OMS906 nearly doubles hemoglobin in patients in less than 3 months
An experimental therapy being developed by Omeros can nearly double the level of hemoglobin safely after three doses in severely anemic people with paroxysmal nocturnal hemoglobinuria (PNH). That’s according to interim data from an ongoing Phase 1b clinical trial that’s evaluating the effect of once-monthly subcutaneous (under-the-skin) injections…